Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study

Objective Preclinical data suggests that memantine, a noncompetitive glutamate N‐methyl‐ D‐aspartate‐receptor blocker used for the treatment of moderate to severe Alzheimer's disease, could reduce depressive and amotivated behavior occurring in the context of psychosocial stress. Therefore, we...

Ausführliche Beschreibung